Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:CLYM NASDAQ:KROS NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$19.40-3.8%$22.91$12.21▼$39.50$543.20M-0.19738,528 shs1.36 million shsCLYMClimb Bio$2.01-1.5%$1.85$1.05▼$8.60$136.21M-0.05361,639 shs422,917 shsKROSKeros Therapeutics$15.80+1.6%$14.66$9.12▼$72.37$641.72M1.06923,130 shs480,977 shsPROKProKidney$2.62+6.9%$2.83$0.46▼$7.13$771.01M1.745.38 million shs1.18 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-13.85%-9.15%+0.10%-15.37%-50.01%CLYMClimb Bio-9.33%-17.41%+7.37%+70.00%+203,999,900.00%KROSKeros Therapeutics-0.70%+0.52%+7.39%+15.53%-72.71%PROKProKidney-1.21%+13.43%+3.81%+185.58%+2.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$19.40-3.8%$22.91$12.21▼$39.50$543.20M-0.19738,528 shs1.36 million shsCLYMClimb Bio$2.01-1.5%$1.85$1.05▼$8.60$136.21M-0.05361,639 shs422,917 shsKROSKeros Therapeutics$15.80+1.6%$14.66$9.12▼$72.37$641.72M1.06923,130 shs480,977 shsPROKProKidney$2.62+6.9%$2.83$0.46▼$7.13$771.01M1.745.38 million shs1.18 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-13.85%-9.15%+0.10%-15.37%-50.01%CLYMClimb Bio-9.33%-17.41%+7.37%+70.00%+203,999,900.00%KROSKeros Therapeutics-0.70%+0.52%+7.39%+15.53%-72.71%PROKProKidney-1.21%+13.43%+3.81%+185.58%+2.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$46.13137.76% UpsideCLYMClimb Bio 3.33Buy$9.00347.76% UpsideKROSKeros Therapeutics 2.50Moderate Buy$30.0089.87% UpsidePROKProKidney 2.33Hold$6.25138.55% UpsideCurrent Analyst Ratings BreakdownLatest CLYM, ANAB, PROK, and KROS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/16/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$45.008/18/2025PROKProKidneyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025CLYMClimb BioBaird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/15/2025CLYMClimb BioRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.008/12/2025ANABAnaptysBioUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.00 ➝ $20.008/8/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $20.008/7/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $45.007/24/2025ANABAnaptysBioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$42.00 ➝ $80.007/15/2025PROKProKidneyUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.00 ➝ $8.007/14/2025PROKProKidneyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00 ➝ $7.007/9/2025PROKProKidneyCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00 ➝ $9.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M5.95N/AN/A$2.33 per share8.33CLYMClimb BioN/AN/AN/AN/A$3.15 per shareN/AKROSKeros Therapeutics$232.84M2.76N/AN/A$14.11 per share1.12PROKProKidney$80K9,637.67N/AN/A($3.41) per share-0.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)CLYMClimb Bio-$73.90M-$0.70N/AN/AN/AN/A-23.10%-22.47%11/11/2025 (Estimated)KROSKeros Therapeutics-$187.35M$0.3150.97N/A2.028.06%2.96%2.74%11/5/2025 (Estimated)PROKProKidney-$61.19M-$0.57N/AN/AN/AN/AN/A-17.11%11/11/2025 (Estimated)Latest CLYM, ANAB, PROK, and KROS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CLYMClimb Bio-$0.19-$0.13+$0.06-$0.13N/AN/A8/12/2025Q2 2025PROKProKidney-$0.14-$0.13+$0.01-$0.13N/A$0.22 million8/6/2025Q2 2025ANABAnaptysBio-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 million8/6/2025Q2 2025KROSKeros Therapeutics-$1.14-$0.76+$0.38-$0.76$3.83 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.228.22CLYMClimb BioN/A14.0814.08KROSKeros TherapeuticsN/A21.1121.11PROKProKidneyN/A11.4811.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ACLYMClimb Bio69.76%KROSKeros Therapeutics71.56%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%CLYMClimb Bio0.80%KROSKeros Therapeutics20.60%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10028.00 million18.62 millionOptionableCLYMClimb Bio967.76 million65.60 millionN/AKROSKeros Therapeutics10040.62 million31.31 millionOptionablePROKProKidney3294.28 million172.18 millionOptionableCLYM, ANAB, PROK, and KROS HeadlinesRecent News About These CompaniesProKidney (NASDAQ:PROK) Shares Down 6.9% - Here's What HappenedSeptember 14 at 11:47 AM | marketbeat.comProKidney (NASDAQ:PROK) Stock Price Down 6.9% - Should You Sell?September 14 at 3:55 AM | americanbankingnews.comProKidney (NASDAQ:PROK) Shares Up 21.1% - Still a Buy?September 13 at 12:38 PM | marketbeat.comProKidney Leads Our Trio Of Promising Penny StocksSeptember 12, 2025 | finance.yahoo.comProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comNuveen LLC Makes New Investment in ProKidney Corp. $PROKSeptember 8, 2025 | marketbeat.comProKidney Corp. (NASDAQ:PROK) Receives $6.25 Consensus Target Price from BrokeragesSeptember 6, 2025 | americanbankingnews.comProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 4, 2025 | marketbeat.comChronic Kidney Disease Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsightSeptember 3, 2025 | theglobeandmail.comProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comProKidney (NASDAQ:PROK) Trading Down 5.6% - What's Next?September 3, 2025 | marketbeat.comProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare ConferenceAugust 27, 2025 | globenewswire.comProKidney (NASDAQ:PROK) Cut to Hold at Zacks ResearchAugust 22, 2025 | marketbeat.comProKidney Corp. (NASDAQ:PROK) Sees Large Decline in Short InterestAugust 21, 2025 | marketbeat.comProKidney (NASDAQ:PROK) Shares Down 6.9% - What's Next?August 21, 2025 | marketbeat.comProKidney (NASDAQ:PROK) Stock Price Up 8.1% - Here's What HappenedAugust 20, 2025 | marketbeat.comProKidney Reports 78 Percent Gain in Q2August 14, 2025 | theglobeandmail.comCiti Reaffirms Their Buy Rating on ProKidney (PROK)August 14, 2025 | theglobeandmail.comProKidney reports larger second-quarter loss as key studies continueAugust 14, 2025 | journalnow.comJProKidney Corp. Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comProKidney reports Q2 EPS (13c), consensus (14c)August 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLYM, ANAB, PROK, and KROS Company DescriptionsAnaptysBio NASDAQ:ANAB$19.40 -0.76 (-3.77%) Closing price 04:00 PM EasternExtended Trading$19.42 +0.02 (+0.10%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Climb Bio NASDAQ:CLYM$2.01 -0.03 (-1.47%) As of 04:00 PM EasternClimb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Keros Therapeutics NASDAQ:KROS$15.80 +0.25 (+1.61%) Closing price 04:00 PM EasternExtended Trading$15.78 -0.02 (-0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.ProKidney NASDAQ:PROK$2.62 +0.17 (+6.94%) Closing price 04:00 PM EasternExtended Trading$2.61 -0.01 (-0.38%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
